Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Rescuers attempt to dig free whale stranded on Germany's Baltic coast - 2Kendall Jenner addresses long-standing rumor about her sexuality
- 3The Best 15 Applications for Efficiency and Association
- 4Spain and Catholic Church agree to compensate sex abuse victims
- 5Skeleton of famed musketeer possibly found in Dutch church
- 5 things for parents to know about changes to kids vaccine schedule
- Ukraine demands army of 800,000 under peace plan
- UPM Adhesive Materials plans new facility near New Delhi, India
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- A definitive Manual for the 5 Off-road Bicycles Available
- Radiated Tortoise Faces Rapid Decline in Madagascar
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Doctors looking into hormone therapy as a way to ward off dementia in women
